Influenza like illness
Conditions
Interventions
Neuraminidase inhibitors including osertamivir, zanamivir, and laninamivir
Kampo formula including maoto for patinets with sweating and makyokansekito for without sweating
watchful waiting
Sponsors
Keio University School of Medicine
Kobe University Hospital Jichi Medical University Hospital Nishitaga National Hospital Hiyoshi Medical Clinic Irako Clinic Ohi Kyodo Clinic Kameda Medical Hospital Ohsaki First Clinic Saiseikai Central Hospital Saiseikai Mukoujima Hospital Kumamoto Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients with influenza like illness who meet all the requirements below 1. axilla temperature equal or higher than 38.0 degree C within the first 48 hours after the onset of fever 2. some symptoms shown below chill sore throat cough headache muscle pain multiple arthrargia general fatigue
Exclusion criteria
Exclusion criteria: 1. patients younger than 19 year-old or older than 65 year-old 2. patients with slight symptoms like subfever or running nose only 3. patients with severe symptoms which need hospitalization 4. persons with chronic pulmonary (including asthma), cardiovascular (except hypertension alone), renal, hepatic, hematological (including sickle cell disease), metabolic disorders (including diabetes mellitus), or neurologic and neurodevelopment conditions (including disorders of the brain, spinal cord, peripheral nerve, and muscle such as cerebral palsy, epilepsy [seizure disorders], stroke, intellectual disability [mental retardation], moderate to severe developmental delay, muscular dystrophy, or spinal cord injury), and active hyperthyroidism 5. patients in danger of urinary retention 6. persons with immunosuppression, including that caused by medications or by HIV infection 7. women who are pregnant or postpartum (within 2 weeks after delivery) 8. persons who are morbidly obese (i.e., body-mass index is equal to or greater than 40) 9. residents of nursing homes and other chronic-care facilities 10. patients considered inappropriate for this trial by the physicians-in-charge including allergic reaction to the test drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients' choice of therapy (Primary outcome about medical cost) Duration of fever (Primary outcome about effectiveness) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of therapy Initial symptoms Dose of antipyretics Adverse event Patients' satisfaction for treatment Vaccination | — |
Countries
Japan
Contacts
Public ContactTetsuhiro Yoshino
Keio University School of Medicine Center for Kampo Medicine
Outcome results
None listed